Edition:
United Kingdom

Novozymes A/S (NZYMb.CO)

NZYMb.CO on Copenhagen Stock Exchange

339.80DKK
17 Aug 2018
Change (% chg)

kr.2.10 (+0.62%)
Prev Close
kr.337.70
Open
kr.337.90
Day's High
kr.340.40
Day's Low
kr.337.10
Volume
310,001
Avg. Vol
541,107
52-wk High
kr.360.70
52-wk Low
kr.288.70

Chart for

About

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and... (more)

Overall

Beta: 1.21
Market Cap(Mil.): kr.83,115.62
Shares Outstanding(Mil.): 251.26
Dividend: 4.00
Yield (%): 1.21

Financials

  NZYMb.CO Industry Sector
P/E (TTM): 32.37 18.45 359.91
EPS (TTM): 10.22 -- --
ROI: 21.71 18.53 10.75
ROE: 28.35 25.90 13.94

Novozymes says Indian tariffs hits sales in its Monsanto alliance in Q1 -CFO

COPENHAGEN, April 25 Danish enzymes maker Novozymes' posted first-quarter earning slightly above forecasts, but sales through its BioAg alliance with U.S. seeds company Monsanto Co were hit by Indian tariffs, its new CFO said on Wednesday.

25 Apr 2018

Novozymes sets up Turkish project to keep flatbreads fresh for longer

COPENHAGEN, April 11 Danish enzymes maker Novozymes has invested in a new lab in Turkey to develop baking enzymes that help to prevent flatbreads traditionally eaten across the Middle East and Africa from going stale.

11 Apr 2018

Novo Holdings launches $165 million 'superbug' drug venture fund

LONDON A $165 million (£119 million) venture fund focused on tackling "superbugs" resistant to modern antibiotics has been launched to invest in small companies working on novel medicines.

28 Feb 2018

Novo Holdings launches $165 million 'superbug' drug venture fund

LONDON A $165 million (119 million pounds) venture fund focused on tackling "superbugs" resistant to modern antibiotics has been launched to invest in small companies working on novel medicines.

28 Feb 2018

Novo Holdings launches $165 mln 'superbug' drug venture fund

LONDON, Feb 28 A $165 million venture fund focused on tackling "superbugs" resistant to modern antibiotics has been launched to invest in small companies working on novel medicines.

28 Feb 2018

Earnings vs. Estimates